A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS) on the Rate of Exacerbations of COPD Following Hospitalization.

Trial Profile

A Randomized, Double-Blind, Parallel Group, Multicenter Study of the Effects of Fluticasone Propionate/Salmeterol Combination Product 250/50mcg BID (ADVAIR DISKUS) in Comparison to Salmeterol 50mcg BID (SEREVENT DISKUS) on the Rate of Exacerbations of COPD Following Hospitalization.

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Salmeterol
  • Indications Chronic obstructive pulmonary disease
  • Focus Therapeutic Use
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 10 Aug 2012 Actual end date (1 Apr 2012) added as reported by ClinicalTrials.gov record.
    • 01 Apr 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 17 Nov 2011 Planned End Date changed from 1 Oct 2011 to 1 Apr 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top